News articles about The Medicines (NASDAQ:MDCO) have been trending positive on Monday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Medicines earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.4526004616869 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Here’s What Short-Term Traders Should Know – The Medicines Company (NASDAQ: MDCO) – Alpha Beta Stock (alphabetastock.com)
- The Medicines (MDCO) to Release Quarterly Earnings on Wednesday (americanbankingnews.com)
- The Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial Results (finance.yahoo.com)
- Focus on Technical Insights: The Medicines Company (MDCO) – Wall Street Morning (wallstreetmorning.com)
- BRIEF-Glaxosmithkline Submits Landmark Impact Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta (feeds.reuters.com)
Several analysts have issued reports on MDCO shares. Chardan Capital reaffirmed a “buy” rating and set a $85.00 price target on shares of The Medicines in a research report on Wednesday, January 24th. Citigroup raised shares of The Medicines from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Monday, January 22nd. Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the company a “buy” rating in a report on Monday, January 15th. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “buy” rating and set a $31.00 price objective on the stock in a report on Tuesday, January 2nd. Finally, Jefferies Group reiterated a “buy” rating and issued a $54.00 price objective on shares of The Medicines in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $51.70.
In other The Medicines news, Director Alexander J. Denner purchased 170,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of $30.03 per share, for a total transaction of $5,105,100.00. Following the completion of the purchase, the director now owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Fredric N. Eshelman purchased 200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average price of $26.56 per share, for a total transaction of $5,312,000.00. Following the completion of the purchase, the insider now directly owns 1,028,383 shares of the company’s stock, valued at approximately $27,313,852.48. The disclosure for this purchase can be found here. 8.22% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This report was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2018/02/19/the-medicines-mdco-earning-positive-press-coverage-accern-reports.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.